Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Should we be stopping new starts of patients who can be triaged for 2-3 months like prostate cancers on ADT when significant community spread of COVID-19 is detectable in our area?

8
9 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

I would for those patients requiring ADT, which is the way I interpreted the question. I want to elaborate more because @Dr. First Last brought up other scenarios we should consider and he brings some more good points: Many patients could get active surveillance for a period of time before ADT is co...

How should radiation oncology departments prepare for significant resource depletion and/or staff shortages with the COVID-19 outbreak?

6
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

Resource depletion to the extreme would be analogous to having a non-operational clinic as some experienced during the Hurricane María disaster. I would suggest reading the paper:Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural ...

How would you manage a small posterior vaginal defect noted at the time of cervical brachytherapy?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

If it is from a disease, I would continue brachy as planned and address the defect based on response and healing. If unrelated to disease, I would have it sutured and continue brachy as planned.

Are there any alternative, hypofractionated RT courses for patients with DLBCL that can be used during the COVID-19 pandemic?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · David Geffen School of Medicine at UCLA

ILROG recently came out with guidelines pasted below: Synopsis of ILROG Recommendations for Administering Radiotherapy for Hematological Malignancies During Emergency Conditions of the COVID-19 Pandemic • We are facing an increased demand for RT to substitute or complement systemic therapy deemed i...

How would you boost a high-risk prostate cancer patient who received standard fractionation treatment and is not able to get LDR boost given COVID-19?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

I will assume for the sake of argument that he is also getting ADT as part of his treatment. If he has responded well to ADT (I like to see about a 90% drop in the PSA within 3 months), my preference would be to try to delay until it's reasonable from an infectious disease perspective to proceed wit...

Do you use either memantine or hippocampal sparing technique to preserve cognitive function when giving whole brain radiotherapy?

4
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Dr. @Dr. First Last and I put together the response below:We use memantine and hippocampal sparing technique for all brain metastasis patients who are planning to receive WBRT. This is based off the recently published phase III trial NRG CC001 that found hippocampal avoidance WBRT plus memantine res...

When do you add a third field for IMPORT-LOW style partial breast irradiation?

3
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I don’t usually use the 3rd field and treat with min tangent with FIF to improve homogeneity. If planning to do conformal RT then prefer an APBI dose of 30 in 5 with VMAT technique.

What are your top takeaways in GU Cancers from ESMO 2025?

6 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Virginia

KEYNOTE-905: These impressive results change the management paradigm of patients with MIBC who are surgical candidates but are not cisplatin-eligible. Over time, it may be that EVP perioperative therapy becomes the standard of care for all patients with MIBC with plans to proceed with cystectomy. I...

How does the POSEIDON meta-analysis results influence your decision on which patients should receive hormone therapy with post-operative radiotherapy for recurrent prostate cancer?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

POSEIDON is another landmark analysis from the MARCAP consortium. It adds to the seminal work performed in localized prostate cancer (Kishan et al., PMID 35051385), which serves as the reference study for the use and duration of ADT with radiotherapy, but now in the post-prostatectomy setting.The st...

What is the preferred palliative regimen for elderly patients with rectal cancer who elect to forego surgery?

4
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Fox Chase Cancer Center

This is a question that comes up somewhat frequently and I don't believe really has a definitive answer. I myself have used multiple regimens in this situation. I think it really depends on the performance status and life expectancy of the particular patient. This is also a topic that may bring out ...